anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adult Studies in CKD on Dialysis

Three 12-week, placebo-controlled studies were conducted in 78 patients with CKD on hemodialysis. In these studies, patients ranged in age from 22 to 90 years, 51% were males, 13% were Caucasian, 79% were African-American, and 8% were Hispanic. The most common causes of renal failure were hypertension and diabetes. The dose of paricalcitol injection was started at 0.04 mcg/kg 3 times per week intravenously. The dose was increased by 0.04 mcg/kg every 2 weeks until intact PTH levels were decreased at least 30% from baseline or a fifth escalation brought the dose to 0.24 mcg/kg, or intact PTH fell to less than 100 pg/mL, or the Ca × P product was greater than 75 within any 2 week period, or serum calcium became greater than 11.5 mg/dL at any time.

Patients treated with paricalcitol injection achieved a mean intact PTH reduction of 30% within 6 weeks. The results from these studies are as follows:

Pediatric Study in CKD on Dialysis

Paricalcitol injection was evaluated in a 12-week randomized, double-blind, placebo-controlled study of 29 pediatric patients, aged 5 to 19 years, with CKD on hemodialysis; nearly all had received some form of vitamin D prior to the study. Of the 29 patients, 76% were male, 52% were Caucasian and 45% were African-American. The initial dose of paricalcitol injection was 0.04 mcg/kg 3 times per week, based on baseline intact PTH level of less than 500 pg/mL, or 0.08 mcg/kg 3 times per week, based on baseline intact PTH level of 500 pg/mL or greater. The dose of paricalcitol injection was adjusted in 0.04 mcg/kg increments based on the levels of serum intact PTH, calcium and Ca × P. The mean baseline levels of intact PTH were 841 pg/mL for the 15 paricalcitol injection-treated patients and 740 pg/mL for the 14 placebo-treated patients. The mean dose of paricalcitol injection administered was 4.6 mcg (range: 0.8 mcg to 9.6 mcg). Sixty-seven percent of the paricalcitol injection-treated patients and 14% of the placebo-treated patients completed the trial. Seventy-one percent of the placebo-treated patients discontinued due to excessive elevations in intact PTH levels, as defined by 2 consecutive intact PTH levels greater than 700 pg/mL and greater than baseline after 4 weeks of treatment. 

The primary efficacy analysis demonstrated that 60% of paricalcitol injection-treated patients and 21% of placebo-treated patients achieved two consecutive greater than or equal to 30% reductions from baseline in intact PTH.
PURPOSE:To obtain the titled composition effectively polymerizable by microwave irradiation for a short time and capable of giving a cured product having high quality, by adding a specific amount of a specific additive to a powdery agent consisting of a methacrylate polymer and a liquid agent consisting of a monomethacrylate monomer. CONSTITUTION:A methacrylate polymer (e.g. methyl methacrylate polymer) used as a main component of a powdery agent is added with a barbituric acid derivative (e.g. 5-n-butylbarbituric acid) and an organic peroxide (e.g. benzoyl peroxide). Separately, a monomethacrylate monomer used as a main component of a liquid agent is added with a crosslinking agent (e.g. diallyl phthalate) and a quaternary ammonium chloride (e.g. lauryldimethylbenzylammonium chloride). The denture base resin composition composed of the above two agents has excellent performance as a resin for microwave polymerization, gives a cured article having uniform structure and free from inner voids and is capable of producing a denture having excellent fitting accuracy.
Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
The role of eosinophils in airway inflammation and asthma pathogenesis is well established, with raised eosinophil counts in blood and sputum associated with increased disease severity and risk of asthma exacerbation. Conversely, there is also preliminary evidence suggesting antiviral properties of eosinophils in the airways. These dual roles for eosinophils are particularly pertinent as respiratory virus infections contribute to asthma exacerbations. Biologic therapies targeting key molecules implicated in eosinophil-associated pathologies have been approved in patients with severe asthma and, therefore, the effects of depleting eosinophils in a clinical setting are of considerable interest. This review discusses the pathological and antiviral roles of eosinophils in asthma and exacerbations. We also highlight the significant reduction in asthma exacerbations seen with biologic therapies, even at the height of the respiratory virus season. Furthermore, we discuss the implications of these findings in relation to the role of eosinophils in inflammation and antiviral responses to respiratory virus infection in asthma.
PCT No. PCT/EP95/00525 Sec. 371 Date Aug. 9, 1996 Sec. 102(e) Date Aug. 9, 1996 PCT Filed Feb. 13, 1995 PCT Pub. No. WO95/22528 PCT Pub. Date Aug. 24, 1995The product 3-amino-2-(4-methoxyphenoxy)pyridine and its pharmaceutically suitable salts, in particular the hydrochloride, are novel products which are prepared by catalytic hydrogenation of 2-(4-methoxyphenoxy)-3-nitropyridine, optionally in the presence of the acid corresponding to the salt. Its pharmaceutical compositions containing sufficient amounts of suitable auxiliaries for its topical administration prove particularly useful in therapy for the treatment of inflammatory skin diseases. The tests for dermatological action with the aid of TPA-induced mouse ear oedema and of carragenan-induced rat paw oedema show that the product is very much more active by the topical route than ibuprofen and nimesulide, two known anti-inflammatory active compounds, of which the first is very widely known and the second structurally related.
FIELD: medicine. ^ SUBSTANCE: invention refers to pharmacology. The method for improving amino acid absorption in a vertebrate, including a mammal and a bird, includes introduction to a vertebrate of AKG (alpha-ketoglutaric acid), mono- and dimetallic AKG salts, chitosan-AKG or their mixtures in amount and/or at rate sufficient to maintain the desired effect. The method for decreasing plasma glucose absorption in a vertebrate, including a mammal and a bird, involves introduction to a vertebrate, including a mammal and a bird, of AKG, mono- and dimetallic AKG salts, chitosan-AKG or their mixtures in amount and/or at rate sufficient to maintain the desired effect of glucose absorption. The method of prevention, inhibition or relief of the condition with high-glucose plasma level in a vertebrate, including a mammal and a bird includes introduction to a vertebrate, including a mammal and a bird, of AKG, mono- and dimetallic AKG salts, chitosan-AKG or their mixtures in amount and/or at rate sufficient to maintain the desired effect on the specified condition. ^ EFFECT: application of AKG, mono- and dimetallic AKG salts, chitosan-AKG or their mixtures in therapeutically effective amount for making the composition used to prevent, relieve and treat the condition with high-glucose plasma level, application of AKG, mono- and dimetallic AKG salts, chitosan-AKG or their mixtures for making the composition used to improve absorption, changed absorption, deteriorated absorption and disordered absorption of amino acids and/or peptides. ^ 19 cl, 3 tbl, 3 ex, 1 dwg
Patients received anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session to assess the potential long term effects of the tDCS.
OBJECTIVES: I. Determine whether event-free survival for children with T-cell non-Hodgkin's lymphoma (NHL) can be improved by the addition of a third intensification block at 35 weeks. II. Determine biology and treatment response of T-cell NHL and T-cell acute lymphocytic leukemia when both are treated with an identical leukemia type protocol and receive a third intensification block. III. Improve the outcome for the 25% of children who are not in remission at eight weeks by the addition of a block of sustained intensification before high dose methotrexate and continuing treatment.

OUTLINE: Patients receive induction therapy on days 1-28. Patients receive supportive oral prednisolone daily for three doses during weeks 1-4, vincristine IV weekly for 5 weeks starting on day 1, asparaginase intramuscularly or subcutaneously three times a week beginning on day 4, and methotrexate intrathecally on days 1 and 8. Patients who meet certain criteria are given first intensification therapy beginning on day 29. Patients receive three doses of oral prednisolone, vincristine IV on day 1, daunorubicin IV over 6 hours on days 1 and 2, etoposide IV over 4 hours on days 1-5, cytarabine IV every 12 hours by bolus injection on days 1-5, oral thioguanine daily on days 1-5, and methotrexate intrathecally as in induction therapy. Patients are followed at 8 weeks. Those patients who experience remission receive a third intensification block at 35 weeks. All patients receive three methotrexate infusions followed by continuation therapy beginning at week 14. As continuation therapy, patients receive oral mercaptopurine daily, oral methotrexate weekly, vincristine IV every 4 weeks, oral prednisolone for 5 days every 4 weeks, and intrathecal methotrexate every 12 weeks beginning at week 23 until 100 weeks from the start of treatment. Continuation therapy will be interrupted at about week 20 for the second intensification therapy. For second intensification therapy, patients receive oral prednisolone daily for 5 days, a single dose of vincristine on day 1, daunorubicin IV over 6 hours on days 1 and 2, etoposide IV over 4 hours on days 1-5, bolus injections of cytarabine every 12 hours on days 1-5, oral thioguanine daily on days 1-5, and intrathecal methotrexate as in induction therapy. Continuation therapy re-starts at week 23. Patients who receive the third intensification therapy will begin at week 35. For the third intensification therapy, patients receive three doses of oral dexamethasone, IV vincristine on day 1 of weeks 35-38, subcutaneous asparaginase for 9 days during weeks 35-38, intrathecal methotrexate on day 1 of weeks 35 and 39, IV cyclophosphamide on day 1 of weeks 39 and 41, subcutaneous or IV cytarabine daily on days 1-4 of weeks 39- 42, and oral thioguanine daily during weeks 39-42. Continuation therapy re-starts at week 42/43. Some patients may receive radiotherapy during chemotherapy. Patients are followed every month for 1 year, every 2 months for the next year, every 6 months for the next 3 years, then annually thereafter.

PROJECTED ACCRUAL: Approximately 100 patients will be accrued for this study within 5 years.
Peripheral neuropathies (PNs) are common diseases in elderly individuals characterized by Schwann cell (SC) dysfunction and irreversible Wallerian degeneration (WD). Although the molecular mechanisms of PN onset and progression have been widely studied, therapeutic opportunities remain limited. In this study, we investigated the pharmacological inhibition of Mammalian Ste20-like kinase 1/2 (MST1/2) by using its chemical inhibitor, XMU-MP-1 (XMU), against WD. XMU treatment suppressed the proliferation, dedifferentiation, and demyelination of SCs in models of WD in vitro, in vivo, and ex vivo. As a downstream mediator of canonical and noncanonical Hippo/MST1 pathway activation, the mature microRNA (miRNA) let-7b and its binding partners quaking homolog (QKI)/nucleolin (NCL) modulated miRNA-mediated silencing of genes involved in protein transport. Hence, direct phosphorylation of QKI and NCL by MST1 might be critical for WD onset and pathogenesis. Moreover, p38α/mitogen-activated protein kinase 14 (p38α) showed a strong affinity for XMU, and therefore, it may be an alternative XMU target for controlling WD in SCs. Taken together, our findings provide new insights into the Hippo/MST pathway function in PNs and suggest that XMU is a novel multitargeted therapeutic for elderly individuals with PNs.
The present invention relates to a traditional Chinese medicine, and especially provides a pure Chinese drug preparation for treating the neck shoulder pain or the lumbocrural pain during the natural balance therapy. The pure Chinese drug preparation comprises the following raw materials in part by weight: 5-10 parts of manis pentadactyla, 5-10 parts of peach kernels, 10-12 parts of carthamus tinctorius, 6-9 parts of asclepias curassavica, 10-15 parts of pawpaw, 7-12 parts of buck grass, 8-10 parts of eucommia, 7-9 parts of rehmanniae radix, 10-15 parts of radix angelicae lateralis preparata grown in west Sichuan, 7-11 parts of pseudo-ginseng and 3-5 parts of borneol. The above raw materials are compatible, clear in division and perform their own functions to bring out the best in each other and reach the focus location. Therefore, the efficacies of promoting blood circulation to remove blood stasis, dispelling wind, eliminating dampness, dispelling wind and eliminating dampness, stimulating the circulation of the blood and cause the muscles and joints to relax, relieving the blood and promoting the circulation of Qi are cooperatively realized. Meanwhile, the muscle elasticity is repaired through the separation of synechia. In this way, the pure Chinese drug preparation has a good restorative effect on deformity, displacement and dysfunction.
The drug being observed in this study is called roflumilast. Roflumilast is used to treat people who have chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis with a history of worsening symptoms. This study looked at side effects and the lung function of people who take roflumilast. The study enrolled 2577 patients who were already prescribed roflumilast as an add on to bronchiodilator treatment by their healthcare provider. This multi-centre trial was conducted in Greece. The overall time to participate in this study was up to 6 months. Participants were evaluated during routine appointments with their healthcare provider.
Acute myeloid leukemia (AML) arises from preleukemic conditions. We have investigated the pathogenesis of typical preleukemia, myeloproliferative neoplasms, and clonal hematopoiesis. Hematopoietic stem cells in both preleukemic conditions harbor recurrent driver mutations; additional mutation provokes further malignant transformation, leading to AML onset. Although genetic alterations are defined as the main cause of malignant transformation, non-genetic factors are also involved in disease progression. In this review, we focus on a non-histone chromatin protein, high mobility group AT-hook2 (HMGA2), and a physiological p53 inhibitor, murine double minute X (MDMX). HMGA2 is mainly overexpressed by dysregulation of microRNAs or mutations in polycomb components, and provokes expansion of preleukemic clones through stem cell signature disruption. MDMX is overexpressed by altered splicing balance in myeloid malignancies. MDMX induces leukemic transformation from preleukemia via suppression of p53 and p53-independent activation of WNT/β-catenin signaling. We also discuss how these non-genetic factors can be targeted for leukemia prevention therapy.
Rationale: Approximately 9-27% of mechanically ventilated patients in the intensive care unit (ICU) develop ventilator-associated pneumonia (VAP). Patients in whom VAP develops have a higher mortality rate up to 50%, stay longer in the intensive care unit (ICU), and require more resources than those without the disease. Despite the availability of modern ICU care and modern antibiotics, the overall clinical cure rate after 72 hours of antibiotic treatment for VAP is only 40%. The cure rate for Pseudomonas aeruginosa is even lower. It is unclear why VAP cure rates are so low. The ATS guidelines recommend IV antibiotic treatment (IV AB), especially directed against gram-negative microorganisms. However, the relatively poor response rates seen with intravenous therapy of VAP and the emergence of MDR organisms makes new treatment options desirable. The ATS/IDSA VAP guidelines recommend that "adjunctive therapy with an inhaled aminoglycoside or polymyxin (colistin) for MDR Gram-negative pneumonia should be considered, especially in patients who are not improving". It is therefore necessary to investigate whether adjunctive therapy with inhalation Tobramycin could ameliorate prognosis. The recommendations by the Society of Infectious Diseases Pharmacists are similar.
Arm A: 60mM of 0.5% Inj. Lignocaine will be injected peri tumoral prior to excision.
The investigators will recruit a total of 30 Chronic Obstructive Pulmonary Disease (COPD) participants from the Temple University Hospital Lung Center Clinic. All participants will have moderate to severe COPD and have a history of 2 or more acute exacerbations in the past year, and eosinophil counts of greater than 300 cells/ul. The investigators studies will include an analysis of the status of the systemic and lung inflammatory phenotype of the major leukocyte populations, using multiparameter flow cytometry. The investigators will couple these studies with an analysis of a panel of inflammatory and anti-inflammatory biomarkers in both the blood and bronchoalveolar lavage fluid. Very importantly, the investigators will characterize the functional capacity of T cells, B cells, monocytes, and granulocytes during drug therapy. By using this approach, the investigators believe a more complete understanding of the scope of activity of mepolizumab at the level of immune competence will be developed.
FIELD: medicine. ^ SUBSTANCE: method involves: producing preparations of donor blood portions, products prepared thereof or by machine apheresis, adding an appropriate photoactive substance and photodynamic exposure to light containing or exclusively consisting of wave length within an absorption region of the photoactive substance, and/or exposure to ultraviolet (UV-) at wave length 200-320 nm. The preparations may consist of many individual, separately stored doses and are kept in flexible flat packages permeable for appropriate exposure. The packages are filled by min. 30% of maximum capacity, and agitated during photodynamic treatment and/or UV exposure so that the package content is mixed to form areas of variable layer thickness of a layer thickness max. 1 mm. The used UV exposure consists of or contains UV-B exposure of wave length max. 320 nm to 280 nm of radiation energy within the range 0.3 to 10 J/cm2 and/or UV-C exposure of wave range max. 280 nm to 200 nm. ^ EFFECT: invention provides sterilisation of separate doses of donor blood, plasma or concentrated erythrocytes of a higher degree of pathogen inactivation in freely arranged packages during agitation for exposure. ^ 26 cl, 5 ex, 5 tbl
Sleepio delivers CBT-I through 6 weekly web-sessions. Treatment content is based on CBT for insomnia manuals and includes a behavioral component (sleep restriction, stimulus control, and relaxation), a cognitive component (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, putting the day to rest) and an educational component (psycho-education, sleep hygiene).
PURPOSE: An antioxidant cosmetic containing a Polygonum aviculare Linne. extract as a main component is provided. Therefore, the extract shows an excellent free radical scavenging effect and has low skin irritation and excellent stability and the cosmetic containing the extract is excellent in prevention of wrinkles and skin aging. CONSTITUTION: The antioxidant cosmetic contains 0.0001 to 5% by weight of an Albizzia julibrissin Duraz. extract, based on the total dried weight of the antioxidant cosmetic. Albizzia julibrissin Duraz. is extracted in C1-3 anhydrous or hydrous alcohol, or ethyl acetate at 4 to 30deg.C for 3 to 20 days and then concentrated to give the Albizzia julibrissin Duraz. extract. In the extracting process, before or after execution of the extraction process, a diethylether soluble component is removed from the extract. For example, 100g Polygonum aviculare Linne. is cut and extracted in 1L ethyl alcohol at room temperature for 10 days, filtered with a filter paper with 300 mesh, left alone for 1 week and then concentrated under reduced pressure after filtering.
NEW MATERIAL:A compound expressed by formula I [R<1> is H, alkali metal or carboxyl protecting group; R<2> is (substituted)alkyl or heterocyclic]. EXAMPLE:(5S)-3-Thio-8-oxo-1-azabicyclo[3.3.0]octa-2-ene-2-carb-oxylic acid. USE:An antimicrobial agent. PREPARATION:For example, pyrrolidine-2-ones expressed by formula II (L is acyl group, etc.) is reacted with N-acetyl-1,3-thiazoline-2-thiones in the presence of tintrifrate to give a compound expressed by formula III (R<4> is H or alkyl). Then the compound expressed by formula III is treated with Mg malonates to afford a compound expressed by formula IV (R<3> is protecting group), which is then diazotized and treated with copper powder, etc., and subjected to ring closure to give a bicyclo compound expressed by formula V, which is further enolized and the enolized bicyclo compound is reacted with a mercapto reagent to provide the compound expressed by formula I.
The invention discloses a Levan-producing microbacterium capable of producing Levan fructan with high yield and application of Levan fructan. The strain is classified and named as a levan-producing microbacterium (A) Microbacteriumlaevaniformans ) CN-01, deposited in 11 days 12 months 2020 to China general microbiological culture Collection center, with the preservation number of CGMCC No.21356. Levan fructan is produced by L-glycan producing microbacterium (A. laevis.) ( M.laevaniformans ) CN-01, and the yield of Levan fructan reaches 35.2g/L after the fermentation condition is optimized. Experiments prove that the Levan fructan secreted by CN-01 has good fat reducing function and good application prospect in the field of weight-reducing food.